An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy of CEP-18770 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 25 Jul 2016
At a glance
- Drugs Delanzomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cephalon
- 31 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
- 31 Jan 2012 New source identified and integrated (M.D. Anderson Cancer Center; 2010-0901).
- 12 Jul 2011 Actual initiation date (Jul 2011) added as reported by ClinicalTrials.gov.